Genmab A/S ADS - ADR Peer Comparison
$56.49
$-0.80
(-1.40%)
As on 29-Oct-2026 16:15EDT
Market cap
$26,927 Mln
Revenue (TTM)
$4,131 Mln
P/E Ratio
31.5
P/B Ratio
3.6
Div. Yield
0 %
Edit
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
26,927 | 54,944 | 2,698 | 2,496 | 1,595 |
Revenue ($ Mln) |
4,131 | 8,446 | 450 | 549 | 121 |
Net Profit ($ Mln) |
788.10 | 2,595.76 | -188.21 | 17.88 | -57.76 |
Net Margin (%) |
19.08 | 30.73 | -41.86 | 3.26 | -47.60 |
RoE (%) |
13.37 | 32.98 | -28.46 | 1.43 | -9.91 |
Price to Earnings |
31.50 | 30.26 | -- | 143.60 | -- |
Price-To-Book |
3.55 | 7.32 | 4.56 | 2.25 | 3.65 |
Income Statement ($ Mln)
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,131.13 | 8,446.25 | 449.61 | 549.12 | 120.79 |
|
Cost of Revenue
|
288.00 | 849.62 | 195.71 | 548.01 | 19.21 |
|
Gross Profit
|
3,413.69 | 3,702.82 | 269.08 | 212.72 | 12.07 |
|
Operating Expenses
|
2,509.03 | 5,385.48 | 517.90 | 35.89 | 154.86 |
|
Operating Profit (EBIT)
|
1,334.10 | 2,441.58 | -264.00 | -34.78 | -118.11 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
906.11 | 2,762.70 | -190.72 | 20.08 | -57.14 |
|
Provision for Tax
|
118.01 | 64.15 | -2.51 | 1.66 | 0.62 |
|
Profit after Tax (Net Income)
|
788.10 | 2,595.76 | -188.21 | 17.88 | -57.50 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
5,957.00 | 8,417.00 | 607.04 | 1,260.78 | 568.41 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
5,418.00 | 40.00 | 39.17 | 186.25 | 123.56 |
|
Current Liabilities
|
1,140.00 | 1,575.00 | 428.58 | 275.21 | 81.11 |
|
Total Liabilities
|
12,843.63 | 8,682.70 | 1,172.38 | 1,753.10 | 784.68 |
Assets ($ Mln)
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
9,714.00 | 1,964.00 | 160.76 | 183.02 | 575.59 |
|
Current Assets
|
2,801.00 | 8,068.00 | 914.04 | 1,553.41 | 197.49 |
|
Total Assets
|
12,843.63 | 8,682.70 | 1,172.38 | 1,753.10 | 784.68 |
|
Total Debt*
|
5,273.00 | 47.00 | 254.58 | 94.51 | 127.33 |
|
Net Current Assets
|
1,661.00 | 6,493.00 | 485.45 | 0.00 | 116.38 |
Cashflow ($ Mln)
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,186.94 | 850.49 | -150.79 | -64.66 | -49.95 |
|
Cash Flow from Investing Activities
|
-5,647.45 | 823.88 | 307.87 | -29.41 | 0.12 |
|
Cash from Financing Activities
|
4,792.78 | 233.73 | 72.35 | 7.84 | 147.34 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
3.93 | 19.96 | -18.15 | 41.92 | -15.42 |
|
ROE (%)
|
13.37 | 32.98 | -28.46 | 1.43 | -10.06 |
|
ROA (%)
|
7.60 | 26.19 | -12.55 | 0.66 | -6.60 |
|
EBIT Margin (%)
|
28.44 | 31.44 | -41.09 | -6.33 | -42.43 |
|
Net Margin (%)
|
19.08 | 30.73 | -41.86 | 3.26 | -47.60 |
|
Cash Profit Margin (%)
|
0.00 | -- | 0.00 | -- | -- |
Growth Ratios
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-68.25 | 130.89 | 5.10 | -8.81 | 602.33 |
|
EBIT Growth (%)
|
-75.80 | 437.07 | 11.36 | -76.55 | 17.93 |
|
Net Profit Growth (%)
|
-85.61 | 89.22 | 11.44 | -96.17 | 43.71 |
|
EPS Growth (%)
|
-85.16 | 98.91 | -1.87 | -96.17 | 47.43 |
|
Book Value Growth (%)
|
12.89 | 40.75 | -25.05 | 2.54 | -6.65 |
Valuation Ratios
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
21.49 | 43.09 | -11.11 | 5.08 | -13.58 |
|
Price / Book Value
|
3.55 | 7.60 | 2.73 | 1.88 | 2.32 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
18.27 | 39.15 | -9.39 | -25.56 | -18.38 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.81 | 0.00 | 0.00 | 0.00 | 0.19 |
|
Short term debt to equity ratio
|
0.05 | 0.00 | 0.40 | 0.02 | 0.02 |
|
Current Ratio
|
2.46 | 5.12 | 2.13 | 5.64 | 2.43 |
|
Quick Ratio
|
2.44 | 4.89 | 1.92 | 5.50 | 2.09 |
|
Interest Coverage
|
4.36 | 554.10 | -30.87 | -19.05 | -4.06 |
Operating Efficiency Ratios
| Genmab A/S ADS - ADR | argenx SE - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
30.98 | 22.98 | 16.23 | 21.41 | 47.25 |
|
Asset Turnover
|
0.40 | 0.85 | 0.30 | 0.20 | 0.14 |
|
Receivable days
|
384.60 | 112.83 | 77.60 | 104.79 | 380.35 |
|
Inventory Days
|
47.22 | 356.92 | 109.55 | 49.57 | 791.94 |
|
Payable days
|
1,259.72 | 652.17 | 231.78 | 47.68 | 931.00 |
|
Cash Conversion Cycle
|
-827.90 | -182.43 | -44.63 | 106.67 | 241.30 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
